Many genetic markers have been associated with variations in treatment response to
analgesics, but none have been assessed in the context of combination therapies. In this …

Aim A finite number of variants in the OPRM1, COMT, MC1R, ABCB1 and CYP2D6 genes
has been identified to significantly modulate the effects of opioids in controlled homogenous …

Despite the various different candidate genetic polymorphisms of potential clinical
relevance, there is not enough understanding of the inter‑individual variability in analgesic …

The pharmacokinetics and pharmacodynamics of morphine are under the control of several
polymorphic genes, which can account for part of the observed interindividual variation in …

Background As pain is often a comorbid condition, many patients use opioid analgesics in
combination with several other drugs. This implies a generally increased risk of drug …

Opioids are used for acute and chronic pain and dependency. They have a narrow
therapeutic index and large interpatient variability in response. Genetic factors regulating …

Genomic variations influencing response to pharmacotherapy of pain are under
investigation. Candidate genes such as (opioid)-receptors, transporters and other molecules …

Interindividual variability in analgesic response is at least partly due to well-characterized
polymorphisms that are associated with opioid dosing and adverse outcomes. The Clinical …

Background: A major challenge for effective pharmacotherapy in pain management is to
provide the drug best suited to the patient's innate characteristics. Objective: The article …

Opioid analgesics are the standards of care for the treatment of moderate to severe
nociceptive pain, particularly in the setting of cancer and surgery. Their analgesic properties …